US FDA approves United's Adcirca, once-daily PAH drug set to rival Pfizer's Revatio
Shares in US drugmaker United Therapeutics jumped 12.7% to $75 - their biggest gain in 18 months - after the Food and Drug Administration approved Adcirca (tadalafil) for the treatment of pulmonary arterial hypertension.
In a note to investors, Deutsche Bank analyst Mark Schoenebaum, said that the label looks to be "a near best-case scenario," and predicts that US sales of the PAH drug could reach $200.0 million before its patent expires in 2017. The drug has already been on the market for year as an erectile dysfunction treatment sold by Eli Lilly as Cialis.
JP Morgan analyst Geoffrey Meacham predicted annual sales in the four years between 2009 and 2012 of $34.0 million, $90.0 million, $153.0 million and $212.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze